Clay B. Siegall

4.4k citations

60 papers · 3.4k indexed · 2 hit papers · h-index 27

Impact in

Biotechnology top 0.5%
- Transgenic Plants and Applications
Radiology, Nuclear Medicine and Imaging top 1%
- Monoclonal and Polyclonal Antibodies Research

Papers in

Biotechnology 26
- Transgenic Plants and Applications 23
- Microbial Inactivation Methods 4
Immunology 50
- Toxin Mechanisms and Immunotoxins 47

Co-authors: Dana F. Chace Joseph A. Francisco Alan F. Wahl Svetlana O. Doronina Peter D. Senter Damon L. Meyer Charles G. Cerveny Brian E. Toki
Journals: Bioconjugate Chemistry (7 papers)The Journal of Immunology (4 papers)Journal of Biological Chemistry (4 papers)Molecular and Cellular Biology (4 papers)Blood (3 papers)
Partner nations: United States Germany Sweden

In The Last Decade

Clay B. Siegall

59 papers receiving 3.2k citations

Hit Papers

align trajectories log scale

Development of potent monoclonal antibody auristatin conjugates for cancer therapy 2003 · 903 citations

Peers

Countries citing papers authored by Clay B. Siegall

Since Specialization

Citations

This map shows the geographic impact of Clay B. Siegall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clay B. Siegall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clay B. Siegall more than expected).

Fields of papers citing papers by Clay B. Siegall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Clay B. Siegall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clay B. Siegall. The network helps show where Clay B. Siegall may publish in the future.

Co-authors

The 25 scholars most cited alongside Clay B. Siegall, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Clay B. Siegall Line = papers co-authored together Clay B. Siegall links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Development of potent monoclonal antibody auristatin conjugates for cancer therapy Nature Biotechnology ·Svetlana O. Doronina, Brian E. Toki, Michael Torgov, Brian A. Mendelsohn, Charles G. Cerveny, Dana F. Chace, Ron L DeBlanc, R Patrick Gearing, Tim D. Bovee, Clay B. Siegall, Joseph A. Francisco, Alan F. Wahl, Damon L. Meyer, Peter D. Senter Hit paper breakdown →	2003	903
2	Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin International Journal of Cancer ·Alan F. Wahl, Karen Donaldson, Bruce Mixan, Pamela A. Trail, Clay B. Siegall	2001	30
3	Single-Chain Immunotoxins Targeted to CD40 for the Treatment of Human B Lineage Hematologic Malignancies Leukemia & lymphoma ·Joseph A. Francisco, Clay B. Siegall	1998	3
4	Identification of a specific tyrosine residue in Bryodin 1 distinct from the active site but required for full catalytic and cytotoxic activity Protein Science ·Daniel K. Fryxell, Susan L. Gawlak, Robert Dodge, Clay B. Siegall	1998	5
5	Agonistic activity of a CD40-specific single-chain Fv constructed from the variable regions of mAb G28-5. PubMed ·J A Ledbetter, J A Francisco, Clay B. Siegall, Lisa K. Gilliland, Diane Hollenbaugh, Alejandro Aruffo, Anthony W. Siadak, N Mischel-Petty, Laura S. Grosmaire, M L Gordon, T J Brown, P Moran-Davis, Robert S. Mittler, Peter A. Kiener, Steven G. Nadler	1997	5
6	Prevention of immunotoxin-induced immunogenicity by coadministration with CTLA4Ig enhances antitumor efficacy The Journal of Immunology ·Clay B. Siegall, Helen G. Haggerty, Garvin L. Warner, Dana F. Chace, Bruce Mixan, Peter S. Linsley, Thomas J. Davidson	1997	26
7	Molecular, Biological, and Preliminary Structural Analysis of Recombinant Bryodin 1, a Ribosome-Inactivating Protein from the PlantBryonia dioica Biochemistry ·Susan L. Gawlak, Michael Neubauer, Herbert E. Klei, Chang, Howard Einspahr, Clay B. Siegall	1997	19
8	Construction, Expression, and Characterization of BD1-G28-5 sFv, a Single-chain Anti-CD40 Immunotoxin Containing the Ribosome-inactivating Protein Bryodin 1 Journal of Biological Chemistry ·Joseph A. Francisco, Susan L. Gawlak, Clay B. Siegall	1997	20
9	Single-Chain Fusion Toxins for the Treatment of Breast Cancer: Antitumor Activity of BR96 sFv-PE40 and Heregulin-PE40 Recent results in cancer research ·Clay B. Siegall	1996	1
10	Targeted therapy of carcinomas using BR96 sFv-PE40, a single-chain immunotoxin that binds to the Leyantigen Seminars in Cancer Biology ·Clay B. Siegall	1995	10
11	Immunoconjugates and Immunotoxins for Therapy of Carcinomas Advances in pharmacology ·Ingegerd Hellström, Karl Erik Hellström, Clay B. Siegall, Pamela A. Trail	1995	11
12	HER4 Expression Correlates with Cytotoxicity Directed by a Heregulin-Toxin Fusion Protein Journal of Biological Chemistry ·Sarah Bacus, D Chin, Andy Goetze, Clay B. Siegall, Bruce D. Cohen, Gregory D. Plowman, Bruce Mixan, Dana F. Chace, Janell M. Green, Ingegerd Hellström, Karl Erik Hellström, H. Perry Fell	1995	20
13	In vivo activities of acidic fibroblast growth factor-Pseudomonas exotoxin fusion proteins Bioconjugate Chemistry ·Clay B. Siegall, Susan L. Gawlak, Dana F. Chace, June Rae Merwin, Ira Pastan	1994	11
14	In vitro and in vivo characterization of BR96 sFv-PE40. A single-chain immunotoxin fusion protein that cures human breast carcinoma xenografts in athymic mice and rats. The Journal of Immunology ·Clay B. Siegall, Dana F. Chace, Bruce Mixan, Ursula Garrigues, Huiying Wan, Lorna Paul, E Wolff, Ingegerd Hellström, K E Hellström	1994	36
15	Characterization of Ribosome-Inactivating Proteins Isolated from Bryonia dioica and Their Utility as Carcinoma-Reactive Immunoconjugates Bioconjugate Chemistry ·Clay B. Siegall, Susan L. Gawlak, Dana F. Chace, E Wolff, Bruce Mixan, Hans Marquardt	1994	20
16	TGFα-PE40 inhibits non-small cell lung cancer growth Life Sciences ·Muriel Draoui, Clay B. Siegall, David Fitzgerald, Ira Pastan, Terry W. Moody	1994	21
17	Basic fibroblast growth factor-Pseudomonas exotoxin chimeric proteins; Comparison with acidic fibroblast growth factor-Pseudomonas exotoxin Bioconjugate Chemistry ·Susan L. Gawlak, Ira Pastan, Clay B. Siegall	1993	11
18	Rational design of a chimeric toxin: an intramolecular location for the insertion of transforming growth factor .alpha. within Pseudomonas exotoxin as a targeting ligand Bioconjugate Chemistry ·R. J. Kreitman, Vijay Chaudhary, Clay B. Siegall, David Fitzgerald, Ira Pastan	1992	19
19	Monoclonal antibody C242-Pseudomonas exotoxin A. A specific and potent immunotoxin with antitumor activity on a human colon cancer xenograft in nude mice. Journal of Clinical Investigation ·Waldemar Debinski, B. Karlsson, Leif Lindholm, Clay B. Siegall, Mark C. Willingham, David FitzGerald, Ira Pastan	1992	31
20	Selective Killing of IL6 Receptor Bearing Myeloma Cells Using Recombinant IL6-Pseudomonas Toxin Current topics in microbiology and immunology ·Clay B. Siegall, David Fitzgerald, Ira Pastan	1990	1

About Clay B. Siegall

Clay B. Siegall is a scholar working on Biotechnology, Immunology, Radiology, Nuclear Medicine and Imaging, Microbiology and Ecology, having authored 60 papers that have together received 3.4k indexed citations. Recurring topics across this work include Toxin Mechanisms and Immunotoxins (47 papers), Monoclonal and Polyclonal Antibodies Research (31 papers), Transgenic Plants and Applications (23 papers), Bacteriophages and microbial interactions (12 papers), HER2/EGFR in Cancer Research (5 papers), Microbial Inactivation Methods (4 papers), Microbial infections and disease research (4 papers) and Bacterial Genetics and Biotechnology (3 papers). The work is most often cited by research in Biotechnology (683 citations), Radiology, Nuclear Medicine and Imaging (1.4k citations), Immunology (1.2k citations), Oncology (1.5k citations) and Pathology and Forensic Medicine (472 citations). Clay B. Siegall has collaborated with scholars based in United States, Germany and Sweden. Frequent co-authors include Dana F. Chace, Joseph A. Francisco, Alan F. Wahl, Svetlana O. Doronina, Peter D. Senter, Damon L. Meyer, Charles G. Cerveny, Brian E. Toki, Ira Pastan and David Fitzgerald. Their work appears in journals such as Bioconjugate Chemistry, The Journal of Immunology, Journal of Biological Chemistry, Molecular and Cellular Biology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact